PUBLIC RELEASE DATE:

7-Jan-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, January 7, 2014African American men have an increased risk of prostate cancer and are two times more likely than Caucasian American men to die from the disease. Despite recent questions about the overall usefulness of prostate-specific antigen (PSA) testing to detect prostate cancer, should PSA screening be used to detect early-stage disease to help save lives in this at-risk population? The controversy is explored in a Review article in Journal of Men's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Men's Health website at http://www.liebertpub.com/jomh.

In the Review "PSA Screening for the African American Male: When and Why?" Tyler Luthringer, Ilija Aleksic, Vladimir Mouraviev, and David Albala, Associated Medical Professionals of NY, PLLC, and SUNY Upstate Medical University, Syracuse, support the American Urological Association's position that early detection of prostate cancer should include multiple parameters to assess personal risk. Together with their physicians, men should decide on an individualized approach to risk assessment and screening, which may include PSA testing and digital rectal examination.

###

Contact

About the Journal

About the Societies

About the Publisher

More:
Increased risk of prostate cancer in African American men; implications for PSA screening

Recommendation and review posted by Bethany Smith

Carp species are found to live successfully in the Great Lakes, but at what price?

Blocking Asian carp from invading the Great Lakes could require an engineering marvel that rivals the reversal of the Chicago River more than a century ago, according to a new federal study that promises to reignite a fierce debate about the region's waterways.

Among the options outlined Monday by the Army Corps of Engineers to thwart the voracious fish and other invasive species from spreading is permanently separating Lake Michigan from the river and its connected waterways. Such a project would restore the once natural divide between the Great Lakes and rivers southwest of Chicago that drain into the Mississippi River.

Chicago blasted through that hydrological barrier when it dug the Sanitary and Ship Canal and Cal-Sag Channel at the turn of the last century to divert the region's sewage away from its source of drinking water. It also created a shipping link between two of the nation's major trade routes.

Separating the lake and the river again could cost more than $18 billion and take up to 25 years, the Corps' study concluded, making that option the most expensive of the eight studied. Another option, carrying a $15 billion price tag, would allow portions of the Chicago River, Sanitary and Ship Canal and Calumet River to flow into Lake Michigan.

Reflecting the development of Chicago from a swampy prairie outpost to a sprawling city, both of those options would require a multibillion investment in giant stormwater tunnels and massive flood-control reservoirs, according to the study.

Several political leaders said the potential cost and time frame could scuttle the plan before Congress considers it.

"I've seen too many of these long-term Corps projects languish for years and fall victim to congressional inaction," said U.S. Sen. Dick Durbin, the Illinois Democrat and assistant Senate majority leader. "We can't gamble with the threat of Asian carp ... or risk severe flood damage to the Chicago metropolitan area by pursuing a risky plan at the expense of our current efforts."

A lobbyist for one of the industries that still relies on the river system was even more blunt. The study "clearly indicates that physical separation is too expensive, too slow and too uncertain to be a viable solution to the spread of invasive species," said Mark Biel, executive director of the Chemical Industry Council of Illinois.

Two years in the making, the study comes amid a series of alarming findings that raise the possibility it might be too late for new federal action to stop Asian carp from getting into the Great Lakes and threatening the region's $7 billion fishing industry.

Follow this link:
Engineering marvel may be needed to stop Asian carp

Recommendation and review posted by Bethany Smith

FARGO Sanford Health is embarking on a major initiative to integrate genetic information with primary care enabled by a $125 million gift from namesake benefactor T. Denny Sanford.

The new effort, announced Tuesday, is billed by Sanford as the first of its kind in the nation to marry genetic screening with internal medicine doctors throughout its clinic system.

The so-called Sanford Imagenetics program will begin offering patients the opportunity for precise genetic testing and genetic counseling later this year.

This is the frontier of medicine, Sanfords top executive, Kelby Krabbenhoft, said in making the announcement. This is whats going to change everything for everybody.

Sanfords gift will allow the health system to hire and train teams of specialists in a collaboration that also will involve academic centers in the Sanford service area for research, and training physicians and other providers.

Each of Sanfords four regional hubs Sioux Falls, S.D., Fargo, Bismarck, and Bemidji, Minn. will have specialists who will work closely with internal medicine doctors.

Sanford already has seven genetic counselors, including two in Fargo, and five medical geneticists.

Through telemedicine and targeted outreach efforts, the program will be available to patients throughout Sanfords sprawling service area that includes North Dakota, South Dakota, Minnesota, Iowa and Montana.

A portion of Sanfords gift will be used for a new genetic medicine center at its campus near downtown Sioux Falls, with construction to begin in spring 2015.

We will have the same resources, said Dr. Julie Blehm, a senior internal medicine doctor at the Sanford Medical Center in Fargo. Were going to have the same opportunities.

Link:
Sanford announces $125 million genetic medicine initiative

Recommendation and review posted by Bethany Smith

FARGO Denny Sanford was recovering from possibly fatal blood clots in his lungs when he decided to invest $125 million to bring genetic medicine into the mainstream.

Sanford became ill on a hunting trip in south-central South Dakota in October, about 140 miles west of Sioux Falls.

Doctors there suspected he had pneumonia, but Sanfords personal physician, Dr. Eric Larson of Sanford Health, suspected a pulmonary embolism a blood clot in the lungs and arranged for an air ambulance to whisk him to Sioux Falls.

He really saved my life, Sanford said in a telephone interview with The Forum, referring to Larson, an internal medicine doctor and one of the champions of the new genetic medicine initiative Sanford Health announced Tuesday.

Sanford, who is in his late 70s, did not attend Tuesdays announcement, which was made in Sioux Falls, and simulcast to Sanford medical centers in Fargo, Bismarck and Bemidji, Minn.

While recuperating in his namesake hospital in Sioux Falls, Sanford reminded Kelby Krabbenhoft, Sanford Healths top executive, that his team was preparing a genetic medicine proposal.

He invited them to make their pitch two days later, when he was convalescing at home. Sanfords recent medical emergency made him receptive to the idea of placing results of genetic testing tools in the hands of primary care physicians.

It was an opportune time to lay it out on me, Sanford said, chuckling about the timing and his gratitude for the care he received.

I believe that is the medicine of the future, added Sanford, referring to the use of genetic information in tailoring health care. He recently donated $100 million to a stem cell research program in California.

Sanford, a St. Paul native who founded Premier Bank, now has donated more than $1 billion, much of it to Sanford Health, beginning with a $400 million gift in 2007.

See original here:
Denny Sanford believes genetic medicine is 'the medicine of the future'

Recommendation and review posted by Bethany Smith

Christmas was two weeks ago but Sanford Health received quite the gift Tuesday morning. $125 Million, that's how much philanthropist Denny Sanford has pledged to help launch a brand new system of patient treatment.

A lot of people will probably just look at the $125 Million and be blown away by the amount, but what that money will do is far more amazing. With the gift, Sanford is launching Imagenetics to fighting disease on the molecular level. This is personalized medicine where your DNA helps determine the best course of treatment. This will help cut down on the number of medications, limit side-effects, and could even help doctors treat the condition before symptoms show up. Genetic medicine is already being utilized by Sanford doctors to treat cancers and other conditions, but this will take those practices to the clinic as well.

"This really gets to what we call precision medicine that is using the tools of genetics to precisely take care of you as an individual." Said Dr. H. Eugene Hoyme, a geneticist and president of Sanford Research.

"Once again he's taken what was possible and today has made it practical for everybody. Thank you Mr. Sanford." Said Kelby Krabbenhoft, president and CEO of Sanford Health.

The money will be spread throughout the Sanford Health system to build facilities for genetic research and testing. Those projects are expected to break ground starting in the spring of 2015.

In addition to the donation, Sanford announced partnerships with Augustana College, and the Universities of North Dakota and South Dakota to train the next wave of genomic health professionals. Krabbenhoft says this donation puts Mr. Sanford over the $1 Billion mark in charitable gifts. His largest donation came back in 2007, giving $400 million dollars to Sanford Health.

Go here to read the rest:
Sanford donates $125M to launch genetic medicine program

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise (Sioux Falls, SD) Sanford Health announced today Denny Sanford, the preeminent health care philanthropist in the United States, will gift the organization $125 million to establish Sanford Imagenetics, a first-of-its-kind program in the country that integrates genomic medicine into primary care for adults.

Mr. Sanfords generosity to this organization is humbling, said Kelby Krabbenhoft, president and CEO of Sanford Health. Including this $125 million gift, Denny has given Sanford Health nearly a billion dollars. Its an incredible honor as well as a tremendous responsibility.

Internal medicine physicians assist adult patients by diagnosing and managing complex health issues. Later this year, Sanford Imagenetics will offer patients the opportunity to undergo precise genetic testing and genetic counseling which will provide internal medicine physicians with unprecedented patient-specific information. Arming these physicians with their patients genetic information will improve their ability to prescribe the right medication, appropriate dose or most effective treatment with drugs such as statins and blood thinners.

Most physicians can only dream of what it would be like to practice not only on the cutting edge of medical advancement but also work to fundamentally change how patients are treated. The creation of this environment does not occur spontaneously. It requires great leadership and generosity at a level not previously seen, said Eric Larson, MD, board-certified internal medicine physician with Sanford Health.

Sanford Health has a long-standing history of providing comprehensive genetic health care to the region. With Sanford Imagenetics, Sanfords MD geneticists, genetic counselors and diagnostic clinical genetics laboratories will move hand in hand with the organizations internal medicines physicians. There are currently no organizations in the country that similarly embed genetics health care professionals into these primary care practices.

Thanks to Mr. Sanfords continued generosity, Sanford Health will take a national lead role in using existing genetic markers and incorporating future discoveries for internists to individualize care for patients with cancer, diabetes, hypertension, coronary artery disease and other conditions, said Dan Blue, MD, president Sanford Clinic.

Sanford Imagenetics will include development of a rigorous research program to define the genomic markers most successful in managing primary care for adults.

We will also study the outcomes to evaluate the efficacy of this approach as well as in-depth bioinformatics research focused on the practical clinical interpretation of the complicated biological data, said Gene Hoyme, MD, president of Sanford Research and board certified geneticist.

Go here to see the original:
Sanford Health Announces $125M Gift to Fund Genomic Initiative for Internal Medicine

Recommendation and review posted by Bethany Smith

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

How is Wall Street supposed to follow up a year like 2013? Boosted by low interest rates, last-minute congressional compromises, and surging real estate markets, stocks posted their highest gains since the 1990s. Unfortunately, the first economic data of 2014 saw four-week average jobless claims jump by 8,500 to more than 357,000, triggering some investors to cash in on last year's profits. After a series of all-time highs to close out December, the Dow Jones Industrial Average (DJINDICES: ^DJI) fell 135 points, or 0.8%, to end at 16,441.

McDonald's (NYSE: MCD) stock, although it fell 0.6% today, wasn't a terrible performer relative to its peers, as 28 of 30 blue chips ended in the red Thursday. The year 2014 should, however, be an interesting one for the international fast-food giant, as a fiercely competitive industry forces McDonald's to rethink its offerings, pricing, and efficiency. The Wall Street Journal called out CEO Don Thompson as one of six head honchos with a lot on the line this year, as slowing sales and so-so new product launches caused the stock to vastly underperform the red-hot stock market.

Elsewhere in the broad-encompassing services sector, Myriad Genetics (NASDAQ: MYGN) stood out as one of the top gainers, adding 3.5%, and resolving to hopefully never repeat 2013's performance. The stock is more than 20% lower than it was just a year ago, although it's worth noting that Myriad Genetics is down more than 10% in the last five days of trading alone. That's because it looks like Medicare won't be willing to dole out what it used to for Myriad's services; the proposed new rate for its BRACAnalysis gene test was actually cut in half. As you might imagine, this didn't go over well with investors.

Another big mover on the day, DryShips (NASDAQ: DRYS) stock, slumped 8.3% to begin 2014 on a very sour note. It was evident that the Greek shipper would get off to a poor start this year after the company announced -- after market close on the last day of the year -- that it would resume its $200 million equity offering. This is an odd turn of events, since just last month, DryShips mysteriously cancelled these same plans, only to reintroduce them weeks later, when the stock was trading at a much higher price.

Two game-changing biotechs revolutionizing the way we treat cancer The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," you will find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read the rest here:
Myriad Genetics Rebounds, DryShips Craters on Surprise ...

Recommendation and review posted by Bethany Smith

Genetics includes the study of heredity, or how traits are passed from parents to offspring. The topics of genetics vary and are constantly changing as we learn more about the genome and how we are influenced by our genes.

Mendel & Inheritance powerpoint presentation covering basics of genetics

Heredity Simulation use popsicle sticks to show how alleles are inherited Penny Genetics flip a coin to compare actual outcomes versus predicted outcomes from a punnett square Heredity Wordsearch fill in the blank, find words

Simple Genetics Practice- using mendelian genetics and punnett squares

Genetic Crosses with two traits basic crosses, uses Punnet squares Genetic Crosses with two traits II- basic crossses, uses Punnett squares Dihybrid Crosses in Guinea Pigs(pdf)- step through on how to do a 44 punnett square

Codominance & Incomplete Dominance- basic crosses involving codominance

Genetics Practice Problems includes codominance, multiple allele traits, polygenic traits, for AP Biology Genetics Practice Problems II- for advanced biology students, includes both single allele and dihybrid crosses, intended for practice after students have learned multiplicative properties of statistics and mathematical analysis of genetic crosses

X-Linked Traits practice crosses that involve sex-linkage, mainly in fruitflies

X Linked Genetics in Calico Cats more practice with sex-linked traits Multiple Allele Traits practice with blood type crosses and other ABO type alleles Multiple Allele Traits in Chickens shows how combs are inherited (rrpp x RRpp) Inheritance and Eye Color uses a simulation to show how multiple alleles can influence a single trait (eye color)

The Genetics of Blood Disorders a worksheet with genetics problems that relate to specific disorders: sickle cell anemia, hemophilia, and Von Willebrand disease.

Read more from the original source:
Genetics | The Biology Corner

Recommendation and review posted by Bethany Smith

Cofounder of Stem Cell Theranostics and StartX Med Divya Nag is attacking one of medicine's biggest problems: the fact that most types of human cellslike those in the heart or liverdie when you keep them in a petri dish. This makes testing new drugs a risky, costly and time-consuming business: 90% of medicines that start clinical trials turn out to be too unsafe or ineffective to market. But a new technology, the induced pluripotent stem cell, may help. Nag's company, Stem Cell Theranostics, was created from technology funded by a $20 million grant from the California Institute of Regenerative Medicine and is closing a venture round. It turns cellsusually from a piece of skininto embryonic-like stem cells, then uses them to create heart cells. These cells can live in petri dishes and be used to test new drugs. Someday they might even replace heart tissue that dies during a heart attack. Three large pharmaceutical companies are customers, though revenues are small. Nag, who was already publishing in prestigious scientific journals when she was an undergraduate, dropped out of Stanford to pursue her dream. No regrets: "Our technology was so promising and I was so passionate about it that nothing else made sense to me," she says. "It was very clear this was what I wanted to do."

Read more here:
2014 30 Under 30: Science & Healthcare

Recommendation and review posted by simmons

Contact Information

Available for logged-in reporters only

Newswise With the help of biomimetic matrices, a research team led by bioengineers at the University of California, San Diego has discovered exactly how calcium phosphate can coax stem cells to become bone-building cells. This work is published in the Proceedings of the National Academy of Sciences the week of Jan. 6, 2014.

UC San Diego Jacobs School of Engineering professor Shyni Varghese and colleagues have traced a surprising pathway from these biomaterials to bone formation. Their findings will help them refine the design of biomaterials that encourage stem cells to give rise to new bone. The researchers say their study may also point out new targets for treating bone defects and bone metabolic disorders such as major fractures and osteoporosis.

The materials are built to mimic the bodys own cellular niches, in which undifferentiated or blank-slate stem cells from bone marrow transform into specific bone-forming cells. We knew for years that calcium phosphate-based materials promote osteogenic differentiation of stem cells, but none of us knew why, Varghese said.

As engineers, we want to build something that is reproducible and consistent, she explained, so we need to know how building factors contribute to this end.

The researchers found that when phosphate ions gradually dissolve from these materials, they are taken up by the stem cells and used for the production of ATP, a key metabolic molecule. An ATP metabolic product called adenosine then signals the stem cells to commit to becoming bone-forming cells.

Varghese said it was a surprise to her team that the biomaterials were connected to metabolic pathways. And we didnt know how these metabolic pathways could influence stem cells commitment to bone formation.

While the PNAS findings only apply to bone building, Varghese and her students at UC San Diego are working on a variety of projects to understand how stem cells thrive and differentiate into a variety of cell types. With this information, they hope to design biomaterials that can be used to help transform stem cells into tissues that may someday replace diseased or degenerated bone, muscle, or blood vessels.

Stem cell research may seem like an unusual endeavor for engineers, but tissue construction and the development of biomaterials have become one more type of building in the engineering repertoire, Varghese said.

Original post:
Biomaterials Get Stem Cells to Commit to a Bony Future

Recommendation and review posted by Bethany Smith

Orange County, CA (PRWEB) January 06, 2014

Top West Coast Stem Cell Clinic, TeleHealth, is now offering stem cell injections for ligament sprains. This includes injuries of the ankle, knee, wrist and other extremity joints. Board Certified doctors administer the outpatient injections which can help patients heal quicker than conventional treatments. For more information and scheduling, call (888) 828-4575.

In adults, ligament sprains can take months to heal due to limited blood supply and healing potential. This can keep athletes off the field and inhibit the ability of even recreational athletes to walk and run without pain.

Conventional pain relief treatments are able to provide pain relief. This may include steroid injections or anti-inflammatories by mouth. However, these treatments do not alter the course of the healing.

With the advent of regenerative medicine treatments, the potential exists for quicker healing. These treatments include fat or bone marrow derived stem cell injections along with platelet rich plasma therapy.

Platelet rich plasma therapy, known as PRP therapy, involves a simple blood draw from the patient. The blood is spun in a centrifuge, which concentrates the platelets and growth factors. These are then injected into the area of ligament injury.

With the fat or bone marrow derived stem cells, the material is harvested in an outpatient procedure from the patient. It is processed immediately to concentrate the patient's stem cells and then injected right away into the injured region.

Small published studies have shown the treatment to be very effective for healing the injuries faster than with conventional treatments. There is low risk involved, the treatments are outpatient and performed by highly experienced Board Certified doctors who have over twenty years combined experience in regenerative medicine treatments.

Along with the injections for ligament injury, stem cell injections are also offered for degenerative arthritis, rotator cuff injury, back and neck pain, achilles tendonitis, plantar fasciitis and more.

TeleHealth has two offices for treatment, one in Orange and a second in Upland, CA. Call (888) 828-4575 for more information and scheduling.

Original post:
West Coast Stem Cell Clinic, TeleHealth, Now Offering Stem Cell Injections for Ligament Sprains

Recommendation and review posted by Bethany Smith

Despite some ethical concerns, most patients are now broadly endorsing stem cell research.

In the case of induced pluripotent stem cells (iPSCs), which are stem cells made from skin or other tissues, researchers at the Johns Hopkins University found patients were largely in favour of participating in iPSC research even if personal benefit was unlikely.

The patients, however, raised concerns about consent, privacy and transparency.

"Bioethicists as well as stem cell researchers and policy-makers have discussed ethical issues at length but till date, we didn't have any systematic information about what patients think about these issues," said Jeremy Sugarman, the Harvey M. Meyerhoff professor of bioethics and medicine at Johns Hopkins Berman Institute of Bioethics.

Unlike human embryonic stem cells, iPSCs are derived without destroying a human embryo. Research with human iPSCs is valuable for developing new drugs, studying disease, and perhaps developing medical treatments, said the study published in the journal Cell Stem Cell.

According to the study, consent was highly important for patients. Some patients even suggested that proper informed consent could compensate for other concerns they had about privacy, the "immortalisation" of cells and the commercialisation of stem cells.

There was a "strong desire among participants to have full disclosure of the anticipated uses, with some participants wanting to be able to veto certain uses of their cells", the study added.

"The idea that donated cells would potentially live forever was unnerving to some participants," the report stated.

"This study is a first step in getting crucial information about what values are factored into a decision to participate in iPSC research, and what those participants expect from the experience," said Sugarman.

Here is the original post:
Patients endorse key stem cell research

Recommendation and review posted by Bethany Smith

Beverly Hills, California (PRWEB) January 06, 2014

The top stem cell clinic in Beverly Hills and Los Angeles, Beverly Hills Institute of Cellular Therapy, is now offering revolutionary stem cell facelift procedures with a New Years pricing special. The procedure involves a nonoperative technique with amniotic stem cells performed by licensed providers. No incisions are necessary, and the outpatient procedures are being offered at 20% off regular price. Call (424) 253-5577 for more information and scheduling.

Traditional facelift procedures involve anesthesia, incisions and significant healing time. A stem cell facelift procedure is performed as an outpatient with no incisions or systemic anesthesia necessary. The Beverly Hills Institute utilizes amniotic stem cells, which are processed at an FDA regulated lab and have been used over 10,000 times without adverse events.

Stem cells have the capability to eliminate wrinkles and provide the skin with a more youthful, glowing appearance. The procedure allows patients to avoid the risks of infection and no stitches are necessary. It costs considerably less than a traditional facelift and now at 20% off is a great option for those desiring to look younger without going through separate procedures for each facial area.

As individuals age, the skin tone in the facial area and texture begin to decline. Stem cells are able to rejuvenate collagen deficient areas and have the capability to change into all types of cells in a procedure that is natural, affordable and safe.

Amniotic fluid is extremely rich in stem cells, growth factors, hyaluronic acid and anti-inflammatory cells. The combination works extremely well for the stem cell facial procedure, with results that are often noticeable quickly and long lasting.

This new technology is performed by licensed aestheticians, nurses and Double Board Certified physicians at the Institute. The procedure takes less than an hour to complete. In addition to the stem cell facelift, the Institute also offers stem cell injections for numerous musculoskeletal conditions including tendon and ligament injury along with degenerative arthritis. This includes stem cell therapy for knees, shoulders and hips.

For more information and scheduling to discuss options with stem cell procedures for looking and feeling younger while avoiding surgery, call the Beverly Hills Institue for Cellular Therapy at (424) 253-5577.

Go here to see the original:
Beverly Hills Institute for Cellular Therapy Now Offering Revolutionary Stem Cell Face Lift Procedure at Special New ...

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

6-Jan-2014

Contact: Ellen Goldbaum goldbaum@buffalo.edu 716-645-4605 University at Buffalo

BUFFALO, N.Y. Researchers at the University at Buffalo have found a way to change alcohol drinking behavior in rodents, using the emerging technique of optogenetics, which uses light to stimulate neurons.

Their work could lead to powerful new ways to treat alcoholism, other addictions, and neurological and mental illnesses; it also helps explain the underlying neurochemical basis of drug addiction.

The findings, published in November in Frontiers in Neuroscience, are the first to demonstrate a causal relationship between the release of dopamine in the brain and drinking behaviors of animals. Research like this, which makes it possible to map the neuronal circuits responsible for specific behaviors, is a major focus of President Obama's Brain Research for Advancing Innovative Neurotechnologies initiative, known as BRAIN.

In the experiments, rats were trained to drink alcohol in a way that mimics human binge-drinking behavior.

First author Caroline E. Bass, PhD, assistant professor of pharmacology and toxicology in the UB School of Medicine and Biomedical Sciences explains: "By stimulating certain dopamine neurons in a precise pattern, resulting in low but prolonged levels of dopamine release, we could prevent the rats from binging. The rats just flat out stopped drinking," she says.

Bass's co-authors are at Wake Forest University, where she worked previously.

Interestingly, the rodents continued to avoid alcohol even after the stimulation of neurons ended, she adds.

See the article here:
Stimulating brain cells stops binge drinking, animal study finds

Recommendation and review posted by Bethany Smith

As scientists get closer to using embryonic stem cells in new treatments for blindness, spinal cord injuries and heart disease, a U.S. legal debate could determine who profits from that research.

Consumer Watchdog, a nonprofit advocacy group, wants an appeals court to invalidate a University of Wisconsin-Madisons patentfor stem cells derived from human embryos, saying its too similar to earlier research. The Santa Monica, California, group also says the U.S. Supreme Courts June ruling limiting ownership rights of human genes should apply to stem cells, a potentially lucrative field for medical breakthroughs.

The challenge to Wisconsin Alumni Research Foundation, the universitys licensing arm, is about whether patents help or hinder U.S. stem-cell research, which has been stymied by political debate. The consumer group says it drives up the cost of research by requiring companies and some academics to pay a licensing fee to the university.

What were asking the government to do is say WARF has no right to the patent, said Dan Ravicher, executive director Public Patent Foundation in New York, which is handling the challenge for Consumer Watchdog. Its like the government sent a check to WARF they didnt deserve.

Consumer Watchdog lost a challenge at the U.S. Patent and Trademark Office in January 2013. It wants the Court of Appeals for the Federal Circuit in Washington to review that decision and consider new arguments based on the Supreme Courts finding that genes -- like stem cells -- are a natural material that cant be patented. Beyond the science question, the case has become a flashpoint over how far members of the public can go to invalidate patents on policy grounds.

While the patent expires in April 2015 and the university has other stem-cell-related patents, Consumer Watchdog is continuing a six-year battle to invalidate it because stem-cell research is starting to get some traction into therapeutic uses, Ravicher said.

The promise of embryonic stem cells is to create or repair tissues and organs using material taken from eggs fertilized in the laboratory. The cells created can be replicated indefinitely, and with the right biological cues, may aid in treating damaged heart tissue and spinal cords, or generate therapies for diabetes and cancer. Companies like StemCells Inc. (STEM) and Advanced Cell Technology Inc. are testing therapies to treat macular degeneration, a cause of blindness.

The next paradigm shift in medicine will be advances in cell therapy -- its under way, said Jason Kolbert, senior biotechnology analyst with Maxim Group LLC in New York. He said pharmaceutical makers such as Teva Pharmaceutical Industries Ltd. (TEVA) of Petach Tikva, Israel, and Pfizer (PFE) Inc. of New York are working with stem-cell researchers on new therapies.

Stem-cell science in the U.S. was curbed in 2001 when then-President George W. Bush issued an executive order limiting research to existing cell lines amid controversy over human embryo destruction, even though they were never in a womans uterus. President Barack Obama reversed that order in 2009.

Some scientists have avoided the public debate by using adult cells to find the unlimited potential they have in embryonic cells.

Read this article:
Gene Patent Case Fuels U.S. Court Test of Stem Cell Right

Recommendation and review posted by Bethany Smith

Current ratings for: Single faulty gene causes major type 2 diabetes symptom in mice

Public / Patient:

5 (1 vote)

Health Professionals:

4.5 (2 votes)

New research from the US reported in the journal Diabetes, shows that the loss of just one gene in mice is enough to cause fasting hyperglycemia - a major symptom of type 2 diabetes.

In their paper, researchers from the College of Medicine at the University of Illinois at Chicago (UIC) explain how malfunctions in insulin-producing pancreatic beta cells is a common feature of type 2 diabetes.

Lead author Bellur S. Prabhakar, professor and head of microbiology and immunology at UIC, says they found that when a gene called MADD is not working properly, insulin is not released into the bloodstream. Lack of insulin means the body is unable to regulate blood sugar or glucose - a major feature of diabetes.

About 8% of Americans and more than 360 million people around the world have type 2 diabetes, a disease that in turn can lead to more serious conditions like cardiovascular disease, kidney failure, blindness, and loss of limbs.

In healthy people without diabetes, the beta cells of the pancreas release insulin into the bloodstream to help regulate blood sugar levels which rise after eating.

See original here:
Single faulty gene causes major type 2 diabetes symptom in mice

Recommendation and review posted by Bethany Smith

Mysterious episodes of genetic duplication in our great ape ancestors may have paved the way for human evolution

By Emily Singer and Quanta Magazine

SRGAP2: Whereas chimps and orangutans have only one, humans have multiple copies of the gene SRGAP2 which is believed to be involved in the development of the brain. Image: Dennis/Cell/Quanta

From Quanta Magazine (find original story here).

About 8 million to 12 million years ago, the ancestor of great apes, including humans, underwent a dramatic genetic change. Small pieces of DNA replicated and spread across their resident chromosomes like dandelions across a lawn. But as these dandelion seeds dispersed, they carried some grass and daisy seeds additional segments of DNA along for the ride. This unusual pattern, repeated in different parts of the genome, is found only in great apes bonobos, chimpanzees, gorillas and humans.

I think its a missing piece of human evolution, said Evan Eichler, a geneticist at the University of Washington, in Seattle. My feeling is that these duplication blocks have been the substrate for the birth of new genes.

Over the past few years, scientists have begun to uncover the function of a handful of genes that reside in these regions; they seem to play an important role in the brain, linked to the growth of new cells, as well as brain size and development. In September, Eichlers team published a new technique for analyzing how these genes vary from person to person, which could shed more light on their function.

Much about the duplication process and its implications remains a mystery. Eichler and others dont know what spurred the initial rounds of duplications or how these regions, dubbed core duplicons, reproduced and moved around the genome.

Despite the duplication-linked genes potential importance in human evolution, most have not been extensively analyzed. The repetitive structure of the duplicated regions makes them particularly difficult to study using standard genetic approaches the most efficient methods for sequencing DNA start by chopping up the genome, reading the sequence of the small chunks and then assembling those sections like one would a puzzle. Trying to assemble repetitive sections is like trying to put together a puzzle made of pieces with almost the same pattern.

Read the original post:
A Missing Genetic Link in Human Evolution

Recommendation and review posted by Bethany Smith

Clinical Chemistry Womens Health Issue Explores the Ethics of Genetic Testing for Reproduction

WASHINGTON, Jan. 6, 2014 /Emag.co.uk/ Jodi Picoults 2004 novel My Sisters Keeper became a bestseller by exploring the fate of a young girl who is genetically engineered to be a donor match for her cancer-stricken older sister. My Sisters Keeper is fiction, but it is based on the reality of preimplantation genetic diagnosis (PGD). A new Q&A in the Advancing Womens Health issue of Clinical Chemistry, the journal of AACC, explores the ethics of PGD, a form of genetic testing that has already made it possible for parents to conceive a child who is a donor match for a sick relative, who shares their minor disability (such as deafness), or to select gender.

(Photo:Listen to a podcast with Q&A moderator Ann M. Gronowski, PhD, and bioethicist Arthur L. Caplan, PhD.

Share this story on Twitter.

PGD was developed after the invention of in vitro fertilization and the ability to culture embryos in vitro, and in many respects, it is similar to the prenatal diagnosis used to screen fetuses for genetic diseases before birth. Its advantage is that it allows parents to choose which embryos to implant in the uterus, thereby avoiding selective pregnancy terminations. For older mothers or couples who are carriers of a genetic disease, the ability to screen for embryos free of certain genetic mutations can play a critical role in ensuring their child is healthy. The more recent and nonstandard uses of PGD listed above, however, have raised ethical concerns, particularly that PGD is veering into the realm of eugenics.

In this Q&A, PGD laboratory director Richard T. Scott, Jr., MD, of Reproductive Medicine Associates of New Jersey, Morristown, N.J.; bioethicist Arthur L. Caplan, PhD, of the New York University Langone Medical Center, New York; and attorney Lawrence J. Nelson, PhD, of Santa Clara University, Santa Clara, Calif., discuss their views on the ethical challenges PGD presents. Former AACC President Ann M. Gronowski, PhD, of the Washington University School of Medicine, St. Louis, acts as moderator.

I think many infertility clinics will be offering PGD for eugenic purposes and there will be plenty of demand for such services, said Caplan, when asked where he thinks the field will be in 20 years. I think there will be a huge ethical controversy concerning the practice, in that competent counseling may not be an essential part of what many clinics are offering. There will also be keen ethical concerns about the equity of access to such services, in that the rich will have far greater access than the poor.

Scott tempers this alarm by pointing out that extensive research is still needed to fully understand which mutations in our genetic code cause disease. By extension, it could be a long time before we grasp the human genomes complexities well enough to optimize traits by rewriting it. Until then, the Clinical Chemistry Q&A aims to raise greater awareness and spark further debate about this complicated issue.

For more, follow us on Twitter at @_AACC and @Clin_Chem_AACC.

Twitter ChatTo add your voice to the conversation, join Dr. Gronowski (@Clin_Chem_AACC) for a Twitter chat on maternal-fetal medicine and reproductive health.

Read this article:
Designing Genes Through Diagnosis

Recommendation and review posted by Bethany Smith

Cancer Genetics, a Rutherford-based clinical diagnostic center that specializes in difficult-to-diagnose cancers, said on Monday its board appointed John Pappajohn as chairman, effective immediately.

Pappajohn, a shareholder of Cancer Genetics, has been involved with more than 100 start-up companies and served as a director of more than 40 public companies, according to a Cancer Genetics news release.

Pappajohn will replace Cancer Genetics founder Raju S.K. Chaganti as chairman. Chaganti will still "play an important role" at Cancer Genetics and will continue to manage the company's scientific advisory board, the news release said.

""The contributions of Dr. Chaganti and his world-class research team in developing the technology behind our unique personalized oncology tests, matched with the disciplined and focused leadership of our CEO Panna Sharma, has positioned the Company for strong future growth," Pappajohn said in the news release. "Our 2013 double-digit revenue growth, our joint venture with Mayo Clinic, and the commercial roll out of five proprietary tests, has already put CGI in an industry-leading position. I plan to help the Company build upon that success."

Cancer Genetics shares rose 39 cents, or 2.89 percent, to $13.89 at 2:56 p.m. in intraday trading Monday on the Nasdaq Stock Market. The company went public in April.

Email: wyrich@northjersey.com Twitter: @AndrewWyrich

Original post:
Rutherford-based Cancer Genetics appoints new chairman

Recommendation and review posted by Bethany Smith

Cellogica
Cellogica is a non-greasy formula that uses revolutionary stem cell technology to regenerate new skin stem cells, prevent the loss of existing skin stem cell...

By: Jordan Kaleb

Originally posted here:
Cellogica - Video

Recommendation and review posted by Bethany Smith

MADISON--After Susan Derse Phillips had chemotherapy for leukemia, she received a stem cell transplant, getting blood-forming cells from a donor to restore her immune system and attack any remaining leukemia cells.

The procedure apparently cured her leukemia, a type of blood cancer. But her skin turned red, her mouth and eyes became dry and she developed diarrhea, fatigue, bronchitis and pneumonia.

She had graft-versus-host disease, or GVHD, a life-threatening complication of the transplant. Her donors cells the graft werent attacking just her leukemia. They were attacking her skin, her gut, her lungs and other organs essentially, her body, the host.

It got pretty scary pretty quickly, said Phillips, 66, of Madison, who continues to struggle with the condition two years after the transplant.

More than half of patients who get donor stem cell transplants develop GVHD, and at least 20 percent of them die from it, said Dr. Mark Juckett, a hematologist at UW Health. But the complication, which likely is under-reported, receives relatively little attention.

Phillips, former president and CEO of Agrace HospiceCare in Fitchburg, set out to change that in Wisconsin. With $500,000 from two donors as seed money, she persuaded UW Health to launch a program to focus on the condition.

UW Carbone Cancer Centers new GVHD program aims to provide better treatment for the 250 or so UW Health patients with the condition and up to 1,000 such patients in Wisconsin and parts of neighboring states, said Juckett, one of the programs two leaders. The program will also study ways to prevent GVHD.

Too often, when doctors give donor stem cell transplants, were trading one disease for another, said Juckett, Phillips doctor. Theres been a lot of focus on how best to do the transplant ... but theres never been a real recognition of dealing with GHVD as a real problem.

Nationwide, about 18,500 stem cell or bone marrow transplants were performed in 2011, according to the Center for International Blood and Marrow Transplant Research in Milwaukee.

At UW Hospital, about 150 patients receive the transplants each year. Roughly 100 of them get infusions of their own stem cells, after high-dose chemotherapy or radiation, for conditions such as multiple myeloma and non-Hodgkins lymphoma. They are not at risk for GVHD.

See the original post here:
Stem cell transplant complication gains attention at UW Health

Recommendation and review posted by Bethany Smith

Regenocyte Adult Stem Cell Therapy - Peter Holler
Patient Peter Holler discusses his health after receiving adult stem cell therapy.

By: RegenocyteStemCells

Read more here:
Regenocyte Adult Stem Cell Therapy - Peter Holler - Video

Recommendation and review posted by Bethany Smith

Regenocyte Adult Stem Cell Therapy-Neim Malo

By: RegenocyteStemCells

See the original post here:
Regenocyte Adult Stem Cell Therapy-Neim Malo - Video

Recommendation and review posted by Bethany Smith

A fight over whether to require genetically modified foods to be labeled in New Hampshire is coming before the House this month.

Supporters argue New Hampshire residents have a right to know whether their food is produced with genetic engineering, but critics say the federal Food and Drug Administration has not mandated the labeling because it determined the foods are safe.

The House Environment and Agriculture Committee split in its recommendation on the bill, with a majority favoring killing it. But a minority is arguing its time for states like New Hampshire to lead, regardless of the federal position on the issue.

While we have concerns about the lack of safety and health testing by parties independent of the bio-tech industry, we are not opposed to the use of (genetic engineering) technology per se. We simply feel that people should have the freedom to make their own choices about food, and since knowledge is essential to the proper exercise of that freedom, information about genetically engineered content should be available on food labels, state Rep. Peter Bixby wrote to the House.

But state Rep. Robert Haefner countered in his message to the House on the bill that a label would in effect serve as a skull and crossbones, suggesting to the consumer that there is something dangerous in the product when in fact science has shown there is not.

Haefner said the bill would be difficult and expensive for the state to enforce.

Follow this link:
GMO bill to go before the House this month

Recommendation and review posted by Bethany Smith

Advanced Genetics, Mod 1.6.4. Review
Muy buenas a todos soy MrSkeletonFull y hoy les traigo un nuevo Mod de minecraft esta vez de la version 1.6.4 Mod: http://www.minecraftforum.net/topic/198882...

By: MrSkeletonFull

Read the original post:
Advanced Genetics, Mod 1.6.4. Review - Video

Recommendation and review posted by Bethany Smith